ImmunityBio is no longer the speculative biotech of its recent past. ANKTIVA, the IL-15 receptor superagonist that received FDA approval for BCG-unresponsive non-muscle invasive bladder cancer in April 2024, has converted into a genuine commercial franchise. Net product revenue reached $50.7 million in the second quarter of 2026. The figure was up sharply year over year and marked the eighth consecutive quarter of sequential growth since the May 2024 launch. Full-year 2025 revenue reached $113 million. The figure represented roughly a 700% jump over the prior year.
The capital structure, however, tells a different story than the revenue line. The company carries a related-party convertible note held by Nant Capital, the vehicle tied to Executive Chairman Patrick Soon-Shiong, alongside warrant and derivative liabilities whose fair-value marks swing with the stock price. The second-quarter net loss was driven in material part by a non-cash revaluation of those instruments, not by operating burn. Cash and marketable securities stood at $357.4 million at the close of the first half. The equity base of roughly 1.06 billion shares means the dilution overhang has not disappeared.
The thesis now hinges on three variables. The first is the PDUFA decision on the papillary-disease supplemental BLA. The second is the readout cadence of the lung cancer trial. The third is whether the bladder franchise can compound faster than the cost base. The stock trades near the middle of a wide 52-week range. At a market cap above $8 billion, the market is already pricing in substantial platform expansion beyond the current indication.
This report argues that ANKTIVA has earned a commercial foothold that the market underpriced in 2024, but that the current multiple demands a platform story that remains unproven in lung cancer. The bear case is not dilution or cash burn. It is the gap between an $8 billion market cap and a product line that, on the most recent annual revenue figure, still generates under $150 million per year.